Alexey Sorokin
Overview
Explore the profile of Alexey Sorokin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciombor K, Bae S, Whisenant J, Ayers G, Sheng Q, Peterson T, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39927885
Purpose: EGFR-targeting monoclonal antibodies are essential for managing RAS WT metastatic colorectal cancer (mCRC), but their limited efficacy necessitates exploring immunological and metabolic factors influencing response. This study evaluated glutamine...
2.
Villarreal O, Xu Y, Tran H, Machado A, Prescod D, Anderson A, et al.
bioRxiv
. 2025 Feb;
PMID: 39896605
MAPK pathway inhibitors (MAPKi) are increasingly used in the treatment of advanced colorectal cancer, but often produce short-lived responses in patients. Although acquired resistance by mutations in tumors have been...
3.
Lee H, Saw A, Morris V, Napolitano S, Bristow C, Srinivasan S, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5166-5179.
PMID: 39269307
Purpose: BRAFV600E-mutated colorectal cancer exhibits a strong correlation with DNA hypermethylation, suggesting that this subgroup of tumors presents unique epigenomic phenotypes. Nonetheless, 5-azacitidine, which inhibits DNA methyltransferase activity, is not...
4.
Takeda M, Theardy M, Sorokin A, Coker O, Kanikarla P, Chen S, et al.
bioRxiv
. 2024 Aug;
PMID: 39211217
The therapeutic benefit of recently developed mutant KRAS (mKRAS) inhibitors has been limited by the rapid onset of resistance. Here, we aimed to delineate the mechanisms underlying acquired resistance to...
5.
Thatikonda V, Lyu H, Jurado S, Kostyrko K, Bristow C, Albrecht C, et al.
Nat Cancer
. 2024 Aug;
5(9):1352-1370.
PMID: 39103541
Combination approaches are needed to strengthen and extend the clinical response to KRAS inhibitors (KRASi). Here, we assessed the antitumor responses of KRAS mutant lung and colorectal cancer models to...
6.
Klomp J, Klomp J, Stalnecker C, Bryant K, Edwards A, Drizyte-Miller K, et al.
Science
. 2024 Jun;
384(6700):eadk0775.
PMID: 38843331
How the oncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal-regulated kinase (ERK)-dependent gene transcription in KRAS-mutant cancer to delineate the...
7.
Napolitano S, Woods M, Lee H, De Falco V, Martini G, Della Corte C, et al.
Clin Cancer Res
. 2023 Apr;
29(12):2299-2309.
PMID: 37040395
Purpose: Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC). However, there is a need to improve the efficacy of this molecular-targeted therapy...
8.
Fan F, Ghosh S, Powell R, Roszik J, Park Y, Sobieski M, et al.
PLoS One
. 2023 Mar;
18(3):e0281063.
PMID: 36952536
Metastatic colorectal cancer (mCRC) is the second leading cause of cancer deaths in the United States. More than 50% of patients with mCRC harbor mutations of the oncogenic driver RAS...
9.
Thatikonda V, Lu H, Jurado S, Kostyrko K, Bristow C, Bosch K, et al.
bioRxiv
. 2023 Feb;
PMID: 36747713
Efforts to improve the anti-tumor response to KRAS targeted therapy have benefited from leveraging combination approaches. Here, we compare the anti-tumor response induced by the SOS1-KRAS interaction inhibitor, BI-3406, combined...
10.
Parseghian C, Sun R, Woods M, Napolitano S, Lee H, Alshenaifi J, et al.
J Clin Oncol
. 2022 Nov;
41(3):460-471.
PMID: 36351210
Purpose: Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in , among...